INTRODUCTION
============

Nocturnal Enuresis (NE) is a very common disorder among children. According to the International Children Continence Society (ICCS), NE is defined as intermittent incontinence occurring exclusively during sleep periods. NE should not be used to refer to daytime incontinence \[[@b1-inj-1632518-259]\]. According to the *Diagnostic and Statistical Manual of Mental Disorders, 5th ed.*, NE is defined as repeated voiding of urine into a bed or clothes while asleep by children older than 5 years, at least twice a week for 3 consecutive months \[[@b2-inj-1632518-259]\].

Children without daytime urinary symptoms have monosymptomatic-NE (MNE), while those who experience symptoms like urgency, frequency, or daytime urinary incontinence have non-MNE \[[@b3-inj-1632518-259]\].

NE can be also classified as primary or secondary: primary MNE (PMNE) occurs in a child who has never attained nocturnal urinary continence, whereas in secondary MNE (SMNE) the disorder appears after the child has achieved a period of at least 6 months of nocturnal dryness. The former condition seems to be related to impaired sleep arousal, nocturnal polyuria, a small nocturnal bladder capacity, or a combination of these factors, while the latter appears to correlate with psychological stress, constipation, urinary tract infections, urge symptoms, diabetes, or obstructive sleep apnoea \[[@b4-inj-1632518-259]\].

The prevalence of NE is above 10% among 6 year-olds, around 5% among 10 year-olds, and 0.5%--1% among teenagers and young adults \[[@b5-inj-1632518-259]-[@b9-inj-1632518-259]\]. An Italian epidemiological study reported an overall NE prevalence of 3.8%, decreasing proportionately with age \[[@b10-inj-1632518-259]\].

The aetiology of the disorder is multifactorial. Indeed, nocturnal NE is a result of a combination of several factors, such as nocturnal polyuria, impaired arousal mechanism, genetic factors, and detrusor overactivity. These children do not secrete adequate antidiuretic hormone at night, have a small bladder capacity and nocturnal detrusor overactivity. They also have a positive family history of NE and they are more difficult to awake from sleep than dry-children \[[@b11-inj-1632518-259]\].

Even if spontaneous remission is frequent, management of NE is important because if left untreated, the disorder can have a deep impact on a child's social development, emotional state, and self-esteem \[[@b12-inj-1632518-259]-[@b14-inj-1632518-259]\].

Both pharmacological and psychological/behavioural interventions can be used. The former involves the use of desmopressin, tricyclic antidepressants, and anticholinergic drugs, whereas the latter includes urotherapy, bedwetting alarms, behavioural interventions, and alternative medicine \[[@b15-inj-1632518-259],[@b16-inj-1632518-259]\].

The first line therapy for patients with PMNE associated with nocturnal polyuria and normal bladder function is desmopressin (dDAVP), which is a synthetic vasopressin analogue, available as a fast-melting oral lyophilisate (MELT).

Even with proper treatment, a number of children do not respond to dDAVP; therefore, other therapies are worth exploring.

The disorder is associated with difficulties in arousal from the sleep and low nocturnal level of vasopressin. These circadian rhythms (sleep-wake cycle and release of endogenous arginine vasopressin \[AVP\]) may play an important role and are associated with circadian melatonin excretion. Moreover, a relationship has been suggested between MNE, difficulties with arousal from sleep, disturbance in circadian rhythms, and nocturnal vasopressin and melatonin secretions \[[@b17-inj-1632518-259]\].

Compared with dry-children, those with MNE have lower peak melatonin levels (pg/mL) at 4.00 (7.00 \[1.95--9.4\] vs. 8.20 \[4.0--23.0\]) and higher levels at 24.00 (5.10 \[2.9--15\] vs. 4.50 \[1.6--6.0\]) \[[@b18-inj-1632518-259]\].

Considering these observations, as well as the fact that melatonin plays an important role in the treatment of several sleep and circadian disorders, melatonin could also be an effective therapeutic remedy in the treatment of MNE \[[@b19-inj-1632518-259]-[@b21-inj-1632518-259]\]. The aim of this study is to evaluate and compare the efficacy of exogenous melatonin associated with different combinations and levels of dDAVP treatment and dietary recommendations.

MATERIALS AND METHODS
=====================

Patients
--------

A total of 189 patients were enrolled from the Service of Paediatrics, Campus Bio-Medico University Hospital of Rome, from January 2013 to June 2015. Of these, 25 were excluded and 11 were lost to follow up.

Hence, the study included 153 children, aged between 5 and 14 years (mean age, 8.7 years).

To be eligible for inclusion, patients had to meet the ICCS definition of NE, while exclusion criteria included treatment within the previous 3 months, non-MNE, SMNE, and history of urinary tract infections.

The eligible children and their families were asked to participate in the study at the end of the clinical evaluation.

All patients had a clinical and anamnestic evaluation. Bladder function was investigated using a bladder diary to collect information about the time and the number of occasions of urination, urinary volume, volume of fluid intake, urinary leakage, activities that provoked it, and signs of urge incontinence. The child's parents kept the diary for 3 months after the enrolment and during the period of observation.

This study was conducted in accordance with the regulatory standards of Good Clinical Practice and the Declaration of Helsinki (1996) and was approved by the Institutional Review Board of Campus Bio-Medico University Hospital.

Study Design
------------

After clinical evaluation and after a 3-month period of observation without treatment, children were randomly assigned to one of 3 treatment groups: group 1, dDAVP at a dose of 120 mcg a day (Minirin melt--oral lyophilisate, Ferring Pharmaceuticals, Saint Prex, Switzerland); group 2, dDAVP at a dose of 120 mcg and dietary recommendations; or group 3, dDAVP at a dose of 120 mcg, dietary recommendations and melatonin at a dose of 1 mg a day (Melamil plus). The dose of dDAVP was gradually increased to 240 mcg, if needed. A simple sequential randomization procedure was used.

The dietary recommendations consisted of a list of recommended food, food not recommended in the evening, and food not recommended at all. The list was designed by reviewing the relevant literature ([Table 1](#t1-inj-1632518-259){ref-type="table"}) \[[@b22-inj-1632518-259]\]. Parents were also given some advice, such as double voiding at bedtime or fluid restriction in the evening.

Each patient was treated for 3 months. During the 3-month period of treatment, all patients and their parents were asked to keep a NE calendar depicting the wet and the dry nights and a food diary. During the follow-up, families were called to verify their adherence and responses to the therapy and dietary recommendations.

Outcome Measures
----------------

The primary outcome was the improvement in the frequency of bedwetting per week and the efficacy of the 3-month period of treatment. Moreover, the number and percentage of nonresponders, partial responders and full responders were evaluated after therapy in each group. Nonresponse is defined as a 0% to 49% decrease, partial response is defined as a 50% to 89% decrease, full response is defined as a 90% or greater decrease in wet nights monthly \[[@b23-inj-1632518-259]\]. We also considered the occurrence of adverse effects.

Statistical Analysis
--------------------

Data were expressed as mean±standard deviation and percentage. A paired-samples t-test and an independent-samples t-test were used for continuous variables; the chi-square test was used for categorical variables. The significance level was set at P\<0.05.

RESULTS
=======

Of the 189 initially enrolled patients, 25 (13%) were excluded for the following reasons: 20 experienced daytime symptoms, 3 had undergone therapy with dDAVP in the previous 3 months, 2 had secondary NE. Of the 164 patients who underwent randomization, 11 were lost to follow-up.

Thus, 153 children were included in our study. Of these, 110 (71.9%) were male and 43 (28.1%) were female, aged between 5 and 14 years (mean age, 8.8 years). Fifty-one patients were assigned to receive dDAVP (group 1), 53 patients received dDAVP and dietary recommendations (group 2), and 49 received dDAVP, dietary recommendations and melatonin (group 3) ([Fig. 1](#f1-inj-1632518-259){ref-type="fig"}). There were no differences in sex, age or family history of enuresis between the 3 groups.

The severity of NE was measured as the mean number of wet nights per week. After the observation period, this was 6.5±0.7 in group 1, 6.3±0.9 in group 2, and 6.28±1.12 in group 3.

The mean number of wet nights after the treatment was 2.4±2.8 in the children treated with dDAVP, 2.3±2.6 in those treated with dDAVP and dietary recommendations, and 2.67±2.68 in those receiving dDAVP, dietary recommendations and melatonin.

After the 3 months of therapy there was a significant difference between wet nights before and after treatment in all of the three groups (P\<0.01).

After the 3 months of therapy a response was achieved in 30 out of 51 children (58.82%) in group 1, 35 of 53 children (66.04%) in group 2, and 35 of 49 children (71.43%) in group 3. These differences are not statistically significant (P=0.41) ([Table 2](#t2-inj-1632518-259){ref-type="table"}). The results are not statistically significant when comparing group 1 with group 3 (P=0.18).

A full response was achieved in 27 children in group 1 (52.94% of all the children of the group and 90% of the responders), 31 children in group 2 (58.49% of all the children of the group and 88.57% of the responders), and 27 children in group 3 (55.10% of all the children of the group and 77.14% of the responders).

A partial response was achieved in 3 children in group 1 (5.88% of all the children of the group and 10% of the responders), 4 children in group 2 (7.55% of all the children of the group and 11.43% of the responders), and 8 children in group 3 (16.33% of all the children of the group and 22.86% of the responders).

The odds of response is the ratio between the probability to respond to treatment and the probability to not. The odds of response for children in G3 is 2.496=(35/49)/(14/49)=(0.714/0.286). The odds of response for children in G1 is 1.427=(30/51)/(21/51) =(0.588/0.412). The odds ratio is the ratio between the 2 odds: 2.496/1.427=1.75.

No adverse effects were reported in the 153 children enrolled in the study.

DISCUSSION
==========

Since NE is a disorder with a complex and multifactorial aetiology, various types of interventions can be used. The pathogenetic factors are detrusor overactivity, difficulties with arousal from sleep, and nocturnal polyuria.

This study evaluated a new approach to therapy, using melatonin in association with dDAVP and dietary recommendations.

Melatonin is a hormone produced by the pineal gland and controlled by the suprachiasmatic nuclei. Its main function is to regulate the circadian rhythm \[[@b24-inj-1632518-259]\].

The levels of the hormone are high during the night, with a peak at 02:00--03:00 AM, and they decrease in the morning. The time of the peak seems to coincide with the time of urine loss in MNE patients, and this means that there might exist a relationship between the production of the hormone and bedwetting. Comparing melatonin levels in saliva between enuretic patients and a control group, Ardura-Fernandez et al. \[[@b18-inj-1632518-259]\] found differences between the groups.

Moreover, melatonin can affect not only the sleep-wake cycle, but also other circadian rhythms, like the release of endogenous AVP; abnormal circadian AVP levels in MNE patients compared to nonenuretic children are described by Rittig et al. \[[@b25-inj-1632518-259]\]. It is also known that exogenous melatonin can shift the phases of circadian rhythms \[[@b26-inj-1632518-259]\].

Another study evaluated the efficacy of exogenous melatonin in enuretic children, leading to the following results: a shift in peak-time and height of the melatonin profile in the group who received melatonin but no changes in enuresis frequency. However, the population of the study was small and consisted of a select group of patients resistant to all other forms of therapy \[[@b27-inj-1632518-259]\].

This study represents the first attempt to evaluate the association between melatonin, dDAVP, and dietary recommendations.

There are some limitations in the study to point out. The sample size was too small and prolonging the research in order to see a more significant rate of resolution is necessary. Moreover, the sleep cycles of the patients were not evaluated in a systematic way. It could be interesting to investigate any possible change in the sleep habits of the children taking melatonin, using, for example, a validated questionnaire. Are these children harder to wake-up? Do their school performances change?

The results show a higher response rate in group 3 vs. group 2 vs. group 1 (71.43% of responders - full and partial - in group 3 versus 66.04% in group 2 vs. 58.82% in group 1).

However, although the preliminary results are not statistically significant, they show a higher rate of responders in the group treated with melatonin. Therefore, these interim results are promising. Moreover, the results may not be statistically significant due to the small sample size.

Another important result is the lack of adverse effects, suggesting that the use of melatonin could be considered as a good and safe treatment for NE. Therefore, the study may be useful to determine a new intervention in order to have a wider spectrum of treatment choices in enuretic patients.

In conclusion, MNE is a common paediatric condition. However, despite several treatment options, a number of children do not respond to therapy, which can be inconvenient and distressing to both children and their families \[[@b28-inj-1632518-259]\]. Moreover, as was shown in several recent studies, persistence of NE can also have some medical consequences \[[@b29-inj-1632518-259]-[@b31-inj-1632518-259]\].

Therefore, other therapeutic approaches are worth exploring.

This is the first time the association between exogenous melatonin, dDAVP and dietary recommendations has been evaluated in the treatment of MNE.

Even though the results are not statistically significant, they show that the association between dDAVP and dietary recommendation and melatonin could be considered a good and safe treatment of NE.

Considering that this could be due to the small sample size, further studies with more participants are needed.
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###### 

List of dietary advises in children with nocturnal enuresis

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Recommended food
   Vegetables: spinach, chard, cauliflower, chicory, cabbage, legumes, tomatoes, eggplant, peppers, beans, cucumbers, asparagus, celery, peas, beans, lettuce, kale
   Fish: tuna, salmon, sardines, sea bream, sole, sea bass
   Seafood
   Dried fruits
   Cereals: gems of oats, wheat buds, puffed rice, corn flakes, wheat bran, muesli
   Eggs
  Not recommended food at evening
   Yogurt
   Water
   Fruit: pineapple, melon, apples, watermelon, apricot, banana
   Milk
   Cheese: mozzarella, cottage cheese, soft cheese, chartreuse
  Not recommended food
   Salt
   Chocolate, cocoa
   Carbonated drinks
   Tea
   Fruit juice: specially grapefruit and orange
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Number and percentage of responders

  Group      Responders   Nonresponders
  ---------- ------------ ---------------
  1          30 (58.82)   21 (41.18)
   Full      27 (52.94)   
   Partial   3 (5.88)     
  2          35 (66.04)   18 (33.96)
   Full      31 (58.49)   
   Partial   4 (7.55)     
  3          35 (71.43)   14 (28.57)
   Full      27 (55.10)   
   Partial   8 (16.33)    

Group 1, desmopressin (dDAVP) at a dose of 120 mcg a day (Minirin); group 2, dDAVP at a dose of 120 mcg and dietary recommendations; group 3, dDAVP at a dose of 120 mcg, dietary recommendations, and melatonin at a dose of 1 mg a day (Melamil plus).
